Sugi Predict

Sugi Predict / Targets / TNIK

TNIK

TRAF2 and NCK-interacting protein kinase · Q9UKE5 · TNIK on Sugi Atlas →

34,498 patent compounds predicted against TNIK, 21,256 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL861559 SCHEMBL861559 0.50 17/20
SCHEMBL721214 SCHEMBL721214 0.85 13/20
SCHEMBL722116 SCHEMBL722116 0.75 13/20
SCHEMBL723895 SCHEMBL723895 0.75 13/20
SCHEMBL723009 SCHEMBL723009 0.68 12/20
SCHEMBL858951 SCHEMBL858951 0.58 12/20
SCHEMBL857280 SCHEMBL857280 0.58 10/20
SCHEMBL721840 SCHEMBL721840 0.62 9/20
SCHEMBL720661 SCHEMBL720661 0.59 9/20
SCHEMBL413621 SCHEMBL413621 0.53 9/20
SCHEMBL722076 SCHEMBL722076 1.00 8/20
SCHEMBL721023 SCHEMBL721023 0.93 8/20
SCHEMBL409688 SCHEMBL409688 0.53 8/20
SCHEMBL415504 SCHEMBL415504 0.52 8/20
SCHEMBL415724 SCHEMBL415724 0.51 8/20
SCHEMBL416872 SCHEMBL416872 0.56 7/20
SCHEMBL878738 SCHEMBL878738 0.55 7/20
SCHEMBL298800 SCHEMBL298800 0.54 7/20
SCHEMBL878650 SCHEMBL878650 0.54 7/20
SCHEMBL414867 SCHEMBL414867 0.53 7/20

Clinical trials — most relevant to TNIK by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis PHASE4NOT_YET_RECRUITING
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors PHASE2RECRUITING
Biological Effects of Quercetin in COPD PHASE1/PHASE2UNKNOWN
Biological Effects of Quercetin in COPD Phase II PHASE2UNKNOWN
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy PHASE2COMPLETED
Doxycycline in Human Pulmonary Tuberculosis PHASE2COMPLETED
Study in Adult Ph-positive ALL PHASE2UNKNOWN
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia PHASE2COMPLETED
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients PHASE2COMPLETED
Valuation of the Safety and Efficacy of Combination of Cryoablation and Dendric Cell/Cytokine-induced Killers Cells Treatment for Advanced Liver Cancers PHASE1/PHASE2UNKNOWN
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 PHASE1COMPLETED
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b PHASE1COMPLETED
Remote Ischaemic Conditioning in Endovascular Recanalization for Proximal Anterior Circulation Occlusion Study PHASE1UNKNOWN
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib nanCOMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors nanACTIVE_NOT_RECRUITING
Novel Biomarkers in Inflammatory Bowel Disease nanCOMPLETED
Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma nanCOMPLETED
Immune Cell Response to Stimuli nanRECRUITING
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome nanCOMPLETED
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study nanCOMPLETED
Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a TNIK binder may also engage these)

ProteinNameSimilarity
P83510 — 1.000 P83510 →
MAP4K4 Mitogen-activated protein kinase kinase kinase kinase 4 1.000 landscape →
P97820 — 1.000 P97820 →
Q9JM52 — 1.000 Q9JM52 →
MINK1 Misshapen-like kinase 1 1.000 landscape →
MAP3K13 Mitogen-activated protein kinase kinase kinase 13 1.000 landscape →
F1LP90 — 0.999 F1LP90 →
A7MBB4 — 0.998 A7MBB4 →
Q148W8 — 0.997 Q148W8 →
Q95Q98 — 0.997 Q95Q98 →
F1QIC4 — 0.997 F1QIC4 →
Q86TC9 — 0.997 Q86TC9 →
CDKL5 Cyclin-dependent kinase-like 5 0.996 landscape →
Q9XTT4 — 0.996 Q9XTT4 →
Q80TZ9 — 0.996 Q80TZ9 →
Q6PEI3 — 0.996 Q6PEI3 →
BMP2K BMP-2-inducible protein kinase 0.996 landscape →
Q6C3D7 — 0.996 Q6C3D7 →
Q17353 — 0.996 Q17353 →
Q23356 — 0.996 Q23356 →
B3M301 — 0.996 B3M301 →
Q5R8X7 — 0.996 Q5R8X7 →
O62090 — 0.996 O62090 →
O61366 — 0.996 O61366 →
P97868 — 0.996 P97868 →
Q9H1K0 — 0.996 Q9H1K0 →
Q0WPH8 — 0.996 Q0WPH8 →
Q92539 — 0.996 Q92539 →
O01700 — 0.995 O01700 →
Q5HZJ0 — 0.995 Q5HZJ0 →